Quality-of-life assessment in comparative therapeutic trials and causal structure considerations in peripheral occlusive arterial disease

被引:3
|
作者
Lehert, P
机构
[1] Univ Mons, Dept Stat, Fucam, Fac Econ, B-7000 Mons, Belgium
[2] Univ Melbourne, Fac Med, Dept Community Hlth, Melbourne, Vic, Australia
关键词
D O I
10.2165/00019053-200119020-00002
中图分类号
F [经济];
学科分类号
02 ;
摘要
When considering the use of quality of life as a primary end-point in phase III to IV comparative trials, the trial designer generally faces some unresolved questions. These include: How does one explain that some dimensions [quality-of-life (QOL) instruments usually have more than I dimension] are directly influenced by the studied treatments whereas others are not? How can one interpret conflicting results between conventional clinical measurements and QOL measurements, when the relationships between conventional clinical measurement and quality of life are not known? In this paper, we consider the use of Structural Equation Modelling (SEM) as a methodological alternative to answer these problems. As an example, we analyse the internal causal structure of the Claudication Scale (CLAU-S), a specific QOL 5-dimensional instrument for peripheral occlusive arterial disease. In applying SEM to different studies and different types of calculation, we suggest that CLAU-S is based on a stable, simple and comprehensive QOL model, is compatible with the general International Classification of Impairments, Disabilities and Handicaps (ICIDH) classification, is coherent and complementary with clinical data measurements and, using differences in a prospective study, considerably improves specificity. We suggest that SEM can help in QOL scale validation, in providing a unified scheme of the inter-relationships between internal dimensions and with external variables, in particular, clinical measurements.
引用
收藏
页码:121 / 130
页数:10
相关论文
共 50 条
  • [42] COMPARATIVE-EVALUATION OF BUFLOMEDIL AND PENTOXIFYLLINE IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
    PIGNOLI, P
    CICCOLO, F
    VILLA, V
    LONGO, T
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1985, 37 (04): : 596 - 606
  • [43] Quality of life in patients with peripheral arterial occlusive disease: Recent insights with ifenprodil - A seminar-in-print - Forward
    Fiessinger, JN
    DRUGS, 1998, 56 : U5 - U5
  • [44] Do we have to change therapeutic considerations in peripheral arterial disease?
    Berent, Robert
    Sinzinger, Helmut
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2018, 47 (01) : 5 - 6
  • [45] QUALITY-OF-LIFE ASSESSMENT IN PATIENTS WITH HEART-DISEASE
    FALLOWFIELD, L
    BRITISH HEART JOURNAL, 1993, 69 (05): : 371 - 372
  • [46] Occlusive and aneurysmal peripheral arterial disease: Assessment of a stent-graft system
    Henry, M
    Amor, M
    Cragg, A
    Porte, JM
    Henry, I
    Amicabile, C
    Tricoche, O
    RADIOLOGY, 1996, 201 (03) : 717 - 724
  • [47] Heel-rise test in the assessment of individuals with peripheral arterial occlusive disease
    Monteiro, Debora Pantuso
    Britto, Raquel Rodrigues
    Ribeiro Lages, Ana Clara
    Basilio, Marluce Lopes
    de Oliveira Pires, Monize Cristine
    Vieira Carvalho, Maria Luiza
    Procopio, Ricardo Jayme
    Gomes Pereira, Danielle Aparecida
    VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 : 29 - 35
  • [48] COURSE OF PERIPHERAL OCCLUSIVE ARTERIAL-DISEASE IN DIABETES - VASCULAR LABORATORY ASSESSMENT
    OSMUNDSON, PJ
    OFALLON, WM
    ZIMMERMAN, BR
    KAZMIER, FJ
    LANGWORTHY, AL
    PALUMBO, PJ
    DIABETES CARE, 1990, 13 (02) : 143 - 152
  • [49] Mild homocysteinaemia in patients with peripheral arterial occlusive disease: Diagnosis, incidence and therapeutic options
    Feussner, A
    Weiss, N
    Keller, C
    Wolfram, G
    ATHEROSCLEROSIS, 1997, 129 (01) : 38 - 38
  • [50] Novel therapies of non-revascularizing peripheral arterial occlusive disease: therapeutic angiogenesis
    Lara-Hernandez, Raul
    Lozano-Vilardell, Pascual
    Cordobes-Gual, Jordi
    MEDICINA CLINICA, 2008, 131 (17): : 665 - 669